BLCO on NYSE

Bausch & Lomb

Logo: Bausch & Lomb Inc, Public domain, via Wikimedia Commons4

Canadian eye health company

Bausch & Lomb (since 2010 stylized as Bausch + Lomb) is a Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb.3 It employed about 12,900 people in 2022.1 Its revenue was $1.5 billion in 2007.1 Its shares trade on NYSE under the symbol BLCO.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1853Founded1

Compare with The Cooper Companies, Alcon or National Vision Holdings, Inc., or pick any stock.

  • TickerBLCO on NYSE1
  • Industrypharmaceutical industry1
  • HeadquartersVaughan1
  • Founded inRochester1
  • Websitewww.bausch.com
  • Legal formjoint-stock company1
John Bausch and Henry Lomb, New York State Men Biographic Studies and Character Portraits (1910)
Photo: The Argus Company, Public domain, via Wikimedia Commons7

Bausch & Lomb (since 2010 stylized as Bausch + Lomb) is a Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

2.2%Operating margin8
-7.1%Net margin8
6.5%Revenue growth, 20258
-5.6%Return on equity8
0.78×Debt to equity8
-$66.0MFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Device Products brought in 38% of the revenue Bausch & Lomb broke down this way in fiscal 2025.

  1. Device Products$1.9B838%up 7% from 2024
  2. Over the Counter Products$1.8B836%up 6% from 2024
  3. Pharmaceutical Products$1.1B821%up 12% from 2024
  4. Branded and Other Generic Products$243.0M85%down 14% from 2024
  5. Other Revenues$21.0M80%up 24% from 2024
  6. Product and Service, Other$21.0M80%up 24% from 2024
Products and services by year
Products and services202320242025
Device Products$1.6B$1.8B$1.9B
Over the Counter Products$1.6B$1.7B$1.8B
Pharmaceutical Products$618.0M$969.0M$1.1B
Branded and Other Generic Products$252.0M$281.0M$243.0M
Other Revenues$15.0M$17.0M$21.0M
Product and Service, Other$15.0M$17.0M$21.0M

Business segments

Vision Care brought in 57% of the revenue Bausch & Lomb broke down this way in fiscal 2025.

  1. Vision Care$2.9B857%up 7% from 2024
  2. Pharmaceuticals$1.3B825%up 6% from 2024
  3. Surgical$894.0M818%up 6% from 2024
Business segments by year
Business segments202320242025
Vision Care$2.5B$2.7B$2.9B
Pharmaceuticals$836.0M$1.2B$1.3B
Surgical$767.0M$843.0M$894.0M

Regions

United States and Puerto Rico brought in 51% of the revenue Bausch & Lomb broke down this way in fiscal 2025.

  1. United States and Puerto Rico$2.5B851%up 6% from 2024
  2. Other Countries$777.0M816%up 9% from 2024
  3. China$358.0M87%up 0% from 2024
  4. France$246.0M85%up 8% from 2024
  5. Japan$186.0M84%up 3% from 2024
  6. Germany$164.0M83%up 8% from 2024
  7. RU$148.0M83%up 23% from 2024
  8. United Kingdom$137.0M83%up 4% from 2024
  9. Canada$135.0M83%up 6% from 2024
  10. Italy$102.0M82%up 12% from 2024
  11. Spain$101.0M82%up 10% from 2024
  12. Mexico$75.0M82%up 0% from 2024
Regions by year
Regions202320242025
United States and Puerto Rico$1.9B$2.4B$2.5B
Other Countries$655.0M$712.0M$777.0M
China$344.0M$358.0M$358.0M
France$210.0M$227.0M$246.0M
Japan$187.0M$180.0M$186.0M
Germany$147.0M$152.0M$164.0M
RU$106.0M$120.0M$148.0M
United Kingdom$121.0M$132.0M$137.0M
Canada$110.0M$127.0M$135.0M
Italy$82.0M$91.0M$102.0M
Spain$85.0M$92.0M$101.0M
Mexico$68.0M$75.0M$75.0M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Selling, general and admin44¢$2.2B
  • Other costs56¢$2.8B
  • Income tax1¢$35.0M

Out of $5.1B in revenue.8 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending100¢$349.0M

Out of $283.0M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.8

Financial statements

Revenue910118$5.1B in 2025+50% since 2020
0$2.0B$4.0B$6.0B2020: $3.4B$3.4B20202021: $3.8B$3.8B2021+10%2022: $3.8B$3.8B2022+0%2023: $4.1B$4.1B2023+10%2024: $4.8B$4.8B2024+16%2025: $5.1B$5.1B2025+6%
Operating income910118$113.0M in 2025−57% since 2020
0$100.0M$200.0M$300.0M$400.0M2020: $260.0M$260.0M20202021: $329.0M$329.0M2021+27%2022: $207.0M$207.0M2022−37%2023: $130.0M$130.0M2023−37%2024: $162.0M$162.0M2024+25%2025: $113.0M$113.0M2025−30%
Net income910118-$360.0M in 2025+1900% since 2020
-$400.0M-$200.0M0$200.0M2020: -$18.0M-$18.0M20202021: $182.0M$182.0M20212022: $6.0M$6.0M2022−97%2023: -$260.0M-$260.0M20232024: -$317.0M-$317.0M2024+22%2025: -$360.0M-$360.0M2025+14%

Every line of the income statement as filed: the last 3 fiscal years, latest first.8

Period ending2025-12-312024-12-312023-12-31
Total revenues$5.1B$4.8B$4.1B
Selling, general and administrative (Note 3)$2.2B$2.1B$1.7B
Research and development$371.0M$343.0M$324.0M
Amortization of intangible assets$258.0M$288.0M$240.0M
Other expense, net$75.0M$44.0M$74.0M
Total expenses$5.0B$4.6B$4.0B
Operating income$113.0M$162.0M$130.0M
Interest income$12.0M$15.0M$15.0M
Interest expense-$421.0M-$399.0M-$283.0M
Loss on extinguishment of debt-$6.0M$0$0
Foreign exchange and other-$15.0M-$12.0M-$28.0M
Loss before provision for income taxes-$317.0M-$234.0M-$166.0M
Provision for income taxes-$35.0M-$71.0M-$82.0M
Net loss-$352.0M-$305.0M-$248.0M
Net income attributable to noncontrolling interest-$8.0M-$12.0M-$12.0M
Net loss attributable to Bausch + Lomb Corporation-$360.0M-$317.0M-$260.0M
Basic loss per share attributable to Bausch + Lomb Corporation (in usd per share)-$1.02-$0.90-$0.74
Diluted loss per share attributable to Bausch + Lomb Corporation (in usd per share)-$1.02-$0.90-$0.74
Basic weighted-average common shares (in shares)353.8M shares351.8M shares350.5M shares
Diluted weighted-average common shares (in shares)353.8M shares351.8M shares350.5M shares

Compare Bausch & Lomb with another company

Corporate structure

Bausch & Lomb sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Bausch & Lomb

  • Bausch & Lomb Vaughan

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

The story

Founded by Henry Lomb and John Jacob Bausch in 1853, in Rochester.1

Early years

In 1853, John Bausch and Henry Lomb, both German immigrants, established a small but ambitious workshop producing monocles in Rochester, New York. By 1861, their operation had expanded to manufacturing vulcanite rubber eyeglass frames and other precision vision products.

During the American Civil War, the Union blockade caused the price of gold and European horn to rise dramatically. This resulted in a growing demand for the Bausch + Lomb spectacles made from vulcanite.

In 1876, Ernst Gundlach joined the company as it began to manufacture microscopes. Later that year, the Bausch & Lomb Optical Company won a distinction at the Philadelphia Centennial Exposition. The company also produced photographic lenses (1883), spectacle lenses (1889), microtomes (1890), binoculars and telescopes (1893). From 1892 in cooperation with Zeiss in Germany, the company produced optical lenses. In this manner, at the end of the 19th century, the product range included eyeglasses, microscopes and binoculars, as well as projectors, camera lenses and camera diaphragms.

20th century

With the growth of the US army, under President Theodore Roosevelt and the buildup of the naval fleet, Bausch & Lomb received the commission, through the supplier Saegmuller, to manufacture high-precision lenses for optical measurement and founded a joint venture with Saegmuller. At the same time as this new expansion, a research department with five members was started to develop new products and improve old ones. A new alliance with the Zeiss company in Germany ensured competitive advantages for the three participants, Bausch & Lomb, Saegmuller and Zeiss, in terms of patent use and opening new markets. In 1902, William Bausch, the son of the founder, developed a process to create the desired lens shape directly by casting molten glass. Previously, the glass parts for the lenses had to be separated, ground and polished in a complicated process, and this brought significant savings in time and materials.

The company produced the first optical-quality glass in America during the early to mid-1900s. By the year 1903 the company began manufacturing microscopes, binoculars, and camera shutters.

The further development of the firm was affected by political events. Because of the World Wars and the consequent need for optical instruments such as field glasses, range finders, camera lenses, binocular telescopes, searchlight mirrors, torpedo tube sights, and periscopes, the product range could be considerably broadened. Until World War I, optical glass and the instruments made from it (including many military instruments) were often imported into most European and North American countries from Germany. The same was also true of chemical products and laboratory equipment. The outbreak of the war, with Germany's new enemy status, created a scramble to rapidly enhance the domestic industries. In 1933, Bausch + Lomb started to honor outstanding high school science students with the Bausch+Lomb Honorary Science Award. In the 1930s, military products represented 70% of total production. The Ray-Ban brand of sunglasses was developed for pilots in 1936.

At a time when the cinema was being superseded by television, Bausch & Lomb developed improved optics for the CinemaScope process, which popularized the film-based anamorphic format and led most cinemas to double the widths of their screens.

In 1965 Bausch & Lomb acquired the patent for the hydrogel contact lenses created by Czech scientists Otto Wichterle and Drahoslav Lím. In 1971, after three years of development work, two years for the medical approval by the United States Food and Drug Administration and an investment of three million USD, Bausch + Lomb launched contact lenses made of Poly-HEMA. In contrast to the contact lenses previously available, made of glass and Lucite (acrylic glass), the new lenses were softer. They were marketed under the brand name "Soflens".

Read the full text

In the 1970s, the company was a major producer of spectrophotometers for the dye and chemical business, such as the Spectronic 20.

A massive restructuring of the company began in the mid-1980s. What had been the core divisions, the production of lenses for various purposes, were sold off. The sunglasses division was continued as Ray-Ban and kept selling well due to effective product placement. By the planned acquisition of other firms, such as Polymer Technology Corporation and Dr. Mann Pharma, existing business areas such as contact lens production were strengthened and new ones were initiated.

In 1997, as a result of a series of company acquisitions, the division for the manufacture of surgical products was established. The Ray-Ban brand was sold in 1999 to the Italian Luxottica Group.

21st century

Since then, Bausch & Lomb has developed into a globally operating company which is one of the largest producers of contact lenses. As of 2022, about 12,900 employees in approximately 100 countries work for the firm.

Competitors in the international eye care products market are Johnson & Johnson, Allergan, Alcon, MSD-Chibret, CooperVision, Menicon Co., Hoya Corporation, EssilorLuxottica and Carl Zeiss Meditec.

In 2023, Bausch + Lomb Corp announced it would buy Xiidra from Novartis for $1.75 billion and pay additional $750 million in linked to future sales for Xiidra as well as two pipeline asset.

In 2025, Bausch + Lomb's subsidiaries closed an offering of $790.6 million.

From Wikipedia’s article on Bausch & Lomb, shared under CC BY-SA 4.0.5

Leadership

Who has led Bausch & Lomb, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (52)

Products and brands

In the last few years, several business areas in the Vision Care division have been developed in the framework of product diversification.

Vision care made $656 million during the first quarter of 2025, with revenua mainly coming from Daily SiHy lenses, Bausch + Lomb ULTRA®, over-the-counter dry eye products, LUMIFY, and eye vitamins.

On July 2, 2004, the company announced that it had licensed the intellectual property of Novartis.

From Wikipedia’s article on Bausch & Lomb, shared under CC BY-SA 4.0.5

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • AcuFocus Australia Pty. Ltd. Australia6
  • AcuFocus Holdings, Inc. Delaware6
  • AcuFocus, Inc. Delaware6
  • Alden Optical Laboratories, Inc. New York6
  • Audrey Enterprise, LLC Delaware6
  • B L E P Holding GmbH Germany6
  • B.L.J. Company Limited Japan6
  • BL Indústria Ótica Ltda. Brazil6
  • Bausch & Lomb (Australia) Pty Ltd Australia6
  • Bausch & Lomb (Hong Kong) Limited Hong Kong6
  • Bausch & Lomb (Malaysia) Sdn. Bhd. Malaysia6
  • Bausch & Lomb (New Zealand) Limited New Zealand6
  • Bausch & Lomb (Shanghai) Trading Co., Ltd. China6
  • Bausch & Lomb (Singapore) Private Limited Singapore6
  • Bausch & Lomb (South Africa) Pty Limited South Africa6
  • Bausch & Lomb (Thailand) Limited Thailand6
  • Bausch & Lomb Americas Inc. Delaware6
  • Bausch & Lomb Argentina S.R.L. Argentina6
  • Bausch & Lomb Australia Holdings Pty Ltd. Australia6
  • Bausch & Lomb Financing LLC Delaware6
  • Bausch & Lomb France France6
  • Bausch & Lomb Gesellschaft m.b.H. Austria6
  • Bausch & Lomb GmbH Germany6
  • Bausch & Lomb Incorporated New York6
All 79 listed subsidiaries
  • Bausch & Lomb India Private Limited India6
  • Bausch & Lomb México Holdings, S.A. de C.V. Mexico6
  • Bausch & Lomb Nordic AB Sweden6
  • Bausch & Lomb Pharma S.A. Belgium6
  • Bausch & Lomb Philippines Inc. Philippines6
  • Bausch & Lomb Poland Spółka z ograniczoną odpowiedzialnością (aka Bausch & Lomb Poland sp. z o.o.) Poland6
  • Bausch & Lomb S.A. Spain6
  • Bausch & Lomb Sağlik ve Optik Ürünleri Ticaret A.Ş. Turkey6
  • Bausch & Lomb Swiss AG Switzerland6
  • Bausch & Lomb Taiwan Limited Taiwan6
  • Bausch & Lomb U.K. Limited United Kingdom6
  • Bausch & Lomb-IOM S.P.A. Italy6
  • Bausch + Lomb Ireland Limited Ireland6
  • Bausch Foundation, LLC Delaware6
  • Bausch Health Hellas Single-Member Pharmaceuticals Société Anonyme (aka Bausch Health Hellas) Greece6
  • Bausch Health LLP Kazakhstan6
  • Bausch Health Limited Liability Company (aka Bausch Health LLC) Russian Federation6
  • Bausch Health Peru, S.R.L. Peru6
  • Bausch Health Romania S.R.L. Romania6
  • Bausch Health Trading DWC - LLC United Arab Emirates6
  • Bausch and Lomb Arabia Regional Headquarters Saudi Arabia6
  • Bausch+Lomb Netherlands B.V. Netherlands6
  • Beijing Bausch & Lomb Eyecare Company Ltd China6
  • Cutting Edge France6
  • Cutting Edge Surgical España Spain6
  • Dr. Gerhard Mann chem.-pharm. Fabrik GmbH Germany6
  • Dr. Mann Limited & Co. KG. Germany6
  • Dr. Robert Winzer Pharma GmbH Germany6
  • ELIOS Vision GmbH Germany6
  • Elios Vision, Inc. Delaware6
  • Grundstückverwaltungsgesellschaft Dr. G.M. chem.-pharm. Fabrik GmbH Germany6
  • Kedalion Therapeutics, Inc. Delaware6
  • Kestrel Ophthalmics Ltd. United Kingdom6
  • Laboratoire Chauvin France6
  • PHARMASWISS društvo s ograničenom odgovornošću za trgovinu i usluge (aka PharmaSwiss d.o.o. Croatia) Croatia6
  • PT Bausch Lomb Indonesia Indonesia6
  • Paragon BioTeck, Inc. Nevada6
  • Servicio Integral De Esterilización, S.L.U. Spain6
  • Servicio Integral Hospitalario, S.L.U. Spain6
  • Shandong Bausch & Lomb Freda New Packaging Materials Co., Ltd. China6
  • Shandong Bausch & Lomb Freda Pharmaceutical Co. Ltd. China6
  • Sino Concept Technology Limited Hong Kong6
  • Soflens (Proprietary) Limited South Africa6
  • Sterimedix Limited United Kingdom6
  • Synergetics IP, Inc. Delaware6
  • Synergetics, Inc. Missouri6
  • TearLab Corporation (d/b/a Trukera Medical) Delaware6
  • TearLab Research, Inc. (d/b/a Trukera Medical) Delaware6
  • Technolas Perfect Vision GmbH Germany6
  • Total Titanium, Inc. Illinois6
  • Valeant Med Spółka z ograniczoną odpowiedzialnością (aka Valeant Med sp z.o.o.) Poland6
  • Waicon Vision S.A. Argentina6
  • Whitecap Biosciences LLC Delaware6
  • Zhejiang Starview Medical Technology Co., Ltd. China6
  • “Bausch Health” Limited Liability Company (aka “Bausch Health” LLC) Ukraine6

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Employees over time

  • 202212,9001
  • 201812,0001

Timeline

  1. Oct 13, 20268-K Executive or director change; Regulation FD disclosure74
  2. Aug 12, 20268-K Executive or director change75
  3. Aug 6, 20268-K Entered a material agreement; Executive or director change; Other events76
  4. Jul 29, 20268-K Results of operations77
  5. May 20, 20268-K Shareholder vote78
  6. Apr 29, 20268-K Results of operations79
  7. Feb 18, 20268-K Results of operations80
  8. Jan 2, 20268-K Entered a material agreement; New debt or obligation; Other events81
  9. Dec 22, 20258-K Executive or director change82
  10. Dec 17, 20258-K Executive or director change83
  11. Dec 12, 20258-K Other events84
  12. Nov 13, 20258-K Regulation FD disclosure85
  13. Mar 6, 2023New chief executive Brent Saunders becomes CEO1
  14. May 9, 2022New chief executive Joseph C. Papa becomes CEO15
  15. Feb 17, 2006New chief executive Ronald L. Zarrella becomes CEO16
  16. 1853Founded Founded in Rochester1

Calendar

Coming up

  1. Oct 28, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $0.18 a share, on Oct 29, 2025.86

When it reported results

  1. Jul 29, 2026Reported quarterly or annual results77
  2. Apr 29, 2026Reported quarterly or annual results79
  3. Feb 18, 2026Reported quarterly or annual results80
  4. Oct 29, 2025Reported quarterly or annual results87
  5. Jul 30, 2025Reported quarterly or annual results88
  6. Apr 30, 2025Reported quarterly or annual results89
  7. Feb 19, 2025Reported quarterly or annual results90
  8. Oct 30, 2024Reported quarterly or annual results91

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

353 filings to the SEC since October 2021: 4 annual reports, 14 quarterly reports, 56 major events, 240 insider forms, 1 large holders, 38 other. The latest 20:

  1. Oct 13, 20268-K EDGAR
  2. Sep 28, 2026144 EDGAR
  3. Aug 14, 20264 PRIMARY DOCUMENT EDGAR
  4. Aug 14, 20263 PRIMARY DOCUMENT EDGAR
  5. Aug 14, 20264 PRIMARY DOCUMENT EDGAR
  6. Aug 14, 20263 PRIMARY DOCUMENT EDGAR
  7. Aug 14, 20264 PRIMARY DOCUMENT EDGAR
  8. Aug 14, 20263 PRIMARY DOCUMENT EDGAR
  9. Aug 14, 20263 PRIMARY DOCUMENT EDGAR
  10. Aug 12, 20264 PRIMARY DOCUMENT EDGAR
  11. Aug 12, 20268-K/A EDGAR
  12. Aug 11, 2026144/A EDGAR
  13. Aug 10, 2026144 EDGAR
  14. Aug 10, 20264 EDGAR
  15. Aug 7, 2026144 EDGAR
  16. Aug 7, 20264 PRIMARY DOCUMENT EDGAR
  17. Aug 7, 20264 PRIMARY DOCUMENT EDGAR
  18. Aug 7, 20264 PRIMARY DOCUMENT EDGAR
  19. Aug 7, 20264 PRIMARY DOCUMENT EDGAR
  20. Aug 7, 20264 PRIMARY DOCUMENT EDGAR

The 353 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Brenton L. SaundersChairman of the Board and Chief Executive Officer56$1.6M$32.2M93
2025Sam A. EldessoukyExecutive Vice President and Chief Financial Officer53$778.0K$5.0M93
2025A. Robert D. BaileyExecutive Vice President and Chief Legal Officer62$767.9K$3.6M93
2025Yehia Hashad, M.D.Executive Vice President of Research & Development and Chief Medical Officer59$726.1K$2.8M93
2025Andrew J. StewartPresident, Global Pharmaceuticals and International Consumer51$629.1K$2.5M93
2024Brenton L. SaundersChairman of the Board and Chief Executive Officer56$1.6M$23.9M93
2024Sam A. EldessoukyExecutive Vice President and Chief Financial Officer53$766.9K$6.8M93
2024A. Robert D. BaileyExecutive Vice President and Chief Legal Officer62$767.4K$5.5M93
2024Yehia Hashad, M.D.Executive Vice President of Research & Development and Chief Medical Officer59$696.8K$4.5M93
2024Andrew J. StewartPresident, Global Pharmaceuticals and International Consumer51$616.3K$4.1M93
2023Brenton L. SaundersChairman of the Board and Chief Executive Officer56$1.4M$45.3M93
2023A. Robert D. BaileyExecutive Vice President and Chief Legal Officer62$519.2K$5.2M93
2023Sam A. EldessoukyExecutive Vice President and Chief Financial Officer53$710.8K$4.8M93
2023Yehia Hashad, M.D.Executive Vice President of Research & Development and Chief Medical Officer59$660.0K$2.7M93
2023Andrew J. StewartPresident, Global Pharmaceuticals and International Consumer51$415.4K$1.9M93

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 97. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Icahn Carl C3,500,000$58.0M0.7%No change
Oaktree Capital Management LP3,441,042$57.0M1.5%+58,303
Deutsche Bank Ag\3,423,046$56.7M0.0%−105,395
D. E. Shaw & Co., Inc.3,323,021$55.0M0.0%+171,854
Davidson Kempner Capital Management LP3,158,972$52.3M1.3%+959,800
Goldentree Asset Management LP2,660,508$44.0M2.6%No change
Caspian Capital LP1,999,043$33.1M18.8%No change
Glenview Capital Management, LLC1,918,148$31.8M0.6%+7,652
Arrowstreet Capital, Limited Partnership1,364,980$22.6M0.0%+382,918
Citadel Advisors LLC987,730$16.4M0.0%+282,509
Clark Estates Inc/ny881,000$14.6M3.4%+56,000
Morgan Stanley703,348$11.6M0.0%−142,566
Clearline Capital LP701,967$11.6M0.8%No change
Whitebox Advisors LLC686,976$11.4M0.6%−414,878
GordonMD Global Investments LP573,472$9.5M4.6%No change
Tudor Investment Corp Et Al532,030$8.8M0.0%+155,584
UBS Group AG465,197$7.7M0.0%+12,018
Goldman Sachs Group Inc420,194$7.0M0.0%+127,308
Sona Asset Management (us) LLC404,279$6.7M0.3%New
Woodline Partners LP386,876$6.4M0.0%No change
Trexquant Investment LP325,766$5.4M0.0%+177,969
Gabelli Funds LLC284,500$4.7M0.0%−23,700
Nomura Holdings Inc255,977$4.2M0.0%−1,000,204
Shenkman Capital Management Inc205,665$3.6M2.0%New
Ballast Asset Management, LP217,470$3.6M1.4%−2,096

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Bausch & Lomb is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBAUSCH & LOMB INC2
  • CIK0000010427
  • Employer ID (EIN)16-03452352
  • Incorporated inNew York2
  • Fiscal year endsOctober 262
  • Industry code (SIC)3851 Ophthalmic Goods2
  • Business addressBausch & Lomb Incorporated, One Bausch & Lomb Place, Rochester, NY 14604-27012
  • Mailing addressOne Bausch & Lomb Place, P O Box 54, Rochester, NY 14604-27012
  • Phone58533860002
  • On EDGAR sinceFeb 9, 19942
  • Filings1,579 in all: 4 (1,127), 8-K (87), SC 13G/A (70), 10-Q (42), SC 13G (27), 3 (17), 10-K (14), 10-Q/A (12)2
    All 52 form types

    DEF 14A (12), DEFA14A (11), DFAN14A (11), 424B3 (10), SC TO-T/A (10), 11-K (9), 15-15D (9), SC TO-I/A (7), 4/A (6), POS AM (6), S-8 (6), 10-K/A (5), 424B2 (5), 424B5 (5), NT 10-Q (5), S-8 POS (5), UPLOAD (5), 25 (4), ARS (4), EFFECT (4), CORRESP (3), NO ACT (3), PRER14A (3), S-3 (3), 25-NSE (2), 3/A (2), 8-A12B (2), 8-K/A (2), NT 10-K (2), PRE 14A (2), PREC14A (2), PREM14A (2), S-3/A (2), SC 13D (2), SC 13D/A (2), SC TO-I (2), 11-K/A (1), 305B2 (1), DEF 14C (1), DEFM14A (1), S-4 (1), S-4/A (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Apr 25, 2007
    Quarterly report (10-Q) Aug 8, 2007
    Proxy statement (DEF 14A) Sep 14, 2007
    Latest 8-K (8-K) Nov 1, 2007

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
    SEC EDGAROther events
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93